LENZ Therapeutics, Inc. - Common Stock LENZ 深 滬
交易中 09-20 15:15:59 美东时间
22.26
+0.180
+0.82%
華盛通- 最 高22.43
- 今 開21.88
- 成交量 7.33万股
- 最 低 21.72
- 昨 收 22.08
- 總市值 1.85亿
- 52周最高 25.77
- 市盈率 靜 --
- 換手率 0.00%
- 52周最低 6.8607
- 委 比 -98.35%
- 總股本 831.96万
- 歷史最高 230.79
- 量 比 0.67
- 振 幅 3.22%
- 歷史最低 3.92
- 每 手 1
- 風險率 5.02%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Piper Sandler Reaffirms Their Buy Rating on LENZ Therapeutics (LENZ)
In a report released today, Joseph Catanzaro from Piper Sandler maintained a Bu...
08-15 18:47
LENZ Therapeutics Analyst Ratings
Unity Software(U.US) reported fourth-quarter financial results after the market...
08-12 19:15
LENS Therapeutics: A Clear Vision for Presbyopia Treatment – Buy Rating Affirmed
Matthew Caufield, an analyst from H.C. Wainwright, has initiated a new Buy rati...
08-12 18:21
LENZ Therapeutics Secures $30 Million Through Private Share Sale
LENZ Therapeutics (LENZ) has issued an announcement. LENZ Therapeutics, Inc. ha...
07-15 20:53
LENZ Therapeutics gets $30M investment from Ridgeback Capital
LENZ Therapeutics (NASDAQ:LENZ) said it is looking to raise $30M through a stock purchase agreement with Ridgeback Capital Investments. Shares in the company were up 7% in premarket trade. The firm in...
07-15 20:12
LENZ Therapeutics Q1 2024 GAAP EPS $(3.53) Misses $(0.90) Estimate
LENZ Therapeutics (NASDAQ:LENZ) reported quarterly losses of $(3.53) per share which missed the analyst consensus estimate of $(0.90) by 292.22 percent. This is a 45.69 percent increase over losses of $(6.50) per share
05-09 04:31
LENZ Therapeutics(LENZ.US)获William Blair首次覆盖，给予优于大市评级。
LENZ Therapeutics(LENZ.US)获William Blair首次覆盖，给予优于大市评级。
04-15 20:11
维持10小时！LENZ Therapeutics(LENZ.US)老花眼眼药水3期结果积极 上市申请递交在即
LENZ Therapeutics(LENZ.US)宣布其两款醋克立定(aceclidine)眼药水配方在治疗老花眼的临床3期试验CLARITY中展现积极结果。
04-04 09:54
LENZ (NASDAQ:LENZ) Soars After Positive Topline Results for Presbyopia Treatment
LENZ Therapeutics (NASDAQ:LENZ) soared in trading after announcing positive top...
04-03 22:55
LENZ Therapeutics To Host Investor Call To Discuss Topline Results From The Phase 3 CLARITY Presbyopia Trials On Wednesday, April 3, 2024, At 8:00 a.m. EST
Conference call and webcast on Wednesday, April 3, 2024, at 8:00 a.m. EST
04-03 04:03
